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ABSTRACT

Approximately 48% of Americans use prescription drugs within each 30-day
period, and there are signs this trend is increasing. Although many studies track
pharmaceuticals’ fates in contaminating waterways, only fairly recent efforts have
examined the potential impacts of these drugs on non-target organisms. The antibiotics
sulfamethoxazole and trimethoprim, often prescribed together to treat bacterial infections,
have been detected worldwide in marine and estuarine environments at concentrations up
to 700-800 ng/L each. Toxic effects of these drugs have been identified in freshwater
organisms, with synergistic effects observed in short-term studies of mixtures of the two;
however, little research has examined possible sub-lethal and longer-term effects of
antibiotics in environmentally-relevant mixture concentrations on marine organisms. I
examined the long-term effects of mixtures of these two antibiotics in species of a marine
system: marine microalgal species, and marine mussels, to determine whether the levels
currently present in waterways affect organism health and reproduction.
Microalgal species may be among the most sensitive organisms to pharmaceutical
contaminants based on ecotoxicity research. I exposed three species of marine microalgae
(Isochrysis galbana, Chaetoceros neogracile, and Nannochloropsis oculata) to
environmentally-relevant mixtures of sulfamethoxazole and trimethoprim and examined
their three-week growth rates. I found that for each species, the antibiotic treatments
significantly suppressed algal growth. Specifically, I found that sulfamethoxazole was a
driving factor in suppression of C. neogracile and I. galbana growth, while N. oculata
responded more sensitively to a broader range of treatment mixture levels, which also
i

included trimethoprim-only treatment groups and mixtures. These results on marine
microalgae address critical data gaps, and identify the impacts of pharmaceuticals on
marine primary producers, which could have direct ecosystem implications to higher
trophic levels.
Antibiotic pharmaceuticals can also affect marine mussel health, based on
previous study of sub-cellular endpoints. I hypothesized that the important benthic
foundational species, the Mytilus californianus mussel, would be significantly impacted
by long-term 12-week exposure to environmentally-relevant concentrations and mixtures
of sulfamethoxazole and trimethoprim. Specifically, I measured growth rate, feeding rate,
condition index, and gonando-somatic index as indicators of whole-organism and
reproductive health. Sulfamethoxazole concentrations, in particular, and trimethoprim to
a lesser extent, suppressed mussel growth and significantly affected condition index and
gonandosomatic index over time. The results of this study offer an understanding of how
an intertidal system responds to chronic presence of antibiotic mixtures in the water, and
a more complete picture of the environmental consequences of pharmaceutical
contaminants released into marine ecosystems at ever-growing rates.
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Chapter 1: Introduction
From 2009-2012, 48.7% of Americans used prescription drugs within any 30-day
period, and data indicate this trend is increasing (Gu et al. 2010, National Center for
Health Statistics 2015). Prescription drugs are a profitable and rapidly growing industry
in the US, with spending on all prescription drugs totaling $234.1 billion in 2008 (more
than double the amount spent in 1999), and currently estimated at approximately $300
billion (Guo 2015, World Health Organization 2016). This figure is expected to grow to
$400 billion within just three years (World Health Organization 2016). Approximately
31% of Americans use two or more prescription drugs in a given 30-day period, with one
in five children, and nine out of 10 elderly people taking drugs during any 30-day period.
For antibiotic prescription drugs in particular, four out of five Americans (80%) use
antibiotics at least once a year (Gu et al. 2010). West Virginia, the state with the highest
usage rate of antibiotics, reported 1,222 prescriptions for antibiotics per every 1,000
people during 2007; thus, some Americans are receiving multiple antibiotic prescriptions
per year (CDDEP 2011).
These pharmaceuticals, which are widely used in both human and veterinary
medicine, find many pathways into the environment (Boxall 2004). Many pharmaceutical
compounds are not fully metabolized by the human body, remaining biologically active
in waste. In turn, onsite and wastewater treatment plant systems fail to remove all
pharmaceuticals before releasing effluent water into the environment. Moreover,
improper disposal of expired or unneeded pharmaceuticals, industrial emissions, and
agricultural uses (e.g., antibiotic use in aquaculture) also contribute to environmental
pollution (Boxall 2004). As a result, a vast array of pharmaceuticals has been detected in
1

marine and freshwater organisms, sediments, and waters at high ng/L levels, and even in
drinking water, with potential unintended effects on non-target organisms and food webs
(Daughton and Ternes 1999). The threat of antibiotic resistance developing due to
environmental exposure to antibiotics and antimicrobials has also caused increasing
concern regarding the growing resistance of pathogenic bacteria in the environment, and
this is a problem that will likely persist and potentially worsen (Kümmerer 2004).
In examining the body of research assessing pharmaceutical effects on aquatic
organisms, there are numerous trends in the type of frequently undertaken studies as well
as clear data gaps. Trends in this field include freshwater organism-focused studies,
assessing acute toxicity of pharmaceuticals at high concentrations (greater than
occurrence data concentrations), and employing short-term exposures (on the order of
hours to days), with single-drug studies. The identified data gaps represent the contrast of
many of these factors: marine organism-focused studies are markedly lacking, and also
studies assessing sub-lethal responses to chronic or longer-term exposures (on the order
of weeks to months) at lower concentrations (Gaw et al. 2014). Additionally, potential
mixture effects of pharmaceuticals have been recognized as vitally important as they
more closely simulate real-world exposures than single-drug studies (Christensen et al.
2006). With the ever-fluctuating cocktails of low levels of pharmaceuticals in waterways,
systematic mixture studies are needed to parse out unknown synergisms. GonzálezPleiter et al. (2013) found from their tests using antibiotic mixtures on freshwater
organisms, “it can be concluded that certain specific combinations may pose a potential
ecological risk for aquatic ecosystems with the present environmentally measured
concentrations.”
2

Current lack of management action on behalf of governing bodies in the form of
preventative measures to lessen impacts of pharmaceutical contaminants may be due to
the fact that the concentrations in which these drugs are detected are often a small
fraction of typical prescribed therapeutic doses for humans and animals. Thus, they are
deemed a low risk to human health, and the World Health Organization (2016) notes that
any form of water safety improvements draws on limited funds and resources that need to
be prioritized based on potential negative impacts to human health. The WHO states that
the implementation of pharmaceutical removal techniques would be extremely costly and
is not currently considered necessary, as there would be a limited human health benefit
(WHO 2016). However, this perspective neglects any sort of ecological implications, and
perhaps dampens the impetus by policymakers or the pharmaceutical industry to make
improved awareness of proper disposal techniques to the public a goal within their
influence spheres.
Pharmaceuticals are specifically designed to elicit a biological response at low
levels, so even low concentrations could impose negative effects on both target and nontarget organisms. The antibiotics sulfamethoxazole (SMX) and trimethoprim (TRI) are
often prescribed together to treat a suite of bacterial infections. In a 5:1 ratio, they
comprise the antibiotic drug Bactrim, which is on the World Health Organization’s List
of Essential Medicines (WHO 2015). Their mode of action is inhibiting synthesis of the
bacterial enzyme tetrahydrofolic acid, a folic acid derivative (Boothe 2015); however,
they interrupt the synthesis chain at two different points, leading to synergistic effects in
combination due to their different target sites (Eguchi et al. 2004). SMX and TRI have
been commonly detected worldwide in marine and estuarine environments, at
3

concentrations up to 870 ng/L for trimethoprim, and 765 ng/L for sulfamethoxazole (Gaw
et al. 2014). Toxicity of these drugs has been identified in freshwater organisms, with
acute synergistic effects observed in mixtures of the two (Eguchi et al. 2004); however,
little research has been conducted examining possible sub-lethal effects on marine
organisms with chronic exposure (weeks to months) at environmentally-relevant
concentrations.
For my MS research project, I examined effects of these two commonly-detected
antibiotics in all mixture combinations including environmentally-relevant high, low and
control levels on (1) 3-week marine microalgal growth rates for Isochrysis galbana,
Chaetoceros neogracile, and Nannochloropsis oculata and (2) 12-week intertidal marine
mussel, Mytilus californianus growth rates, feeding rates, and reproductive and condition
indices (Figure 1). In separate simulations using a laboratory temperature/ lightcontrolled tank set-up, I measured these endpoints to parse out independent effects; I also
consider potential interactive trophic effects within the food chain. I hypothesize that,
based on the known microalgal sensitivities to pharmaceuticals, documented mussel subcellular immuno-sensitivity health responses to antibiotics, and the synergistic nature of
SMX and TRI, algal growth over time will be suppressed, and growth and health
indicators of marine mussels will be suppressed (Isidori et al. 2005, Guo et al. 2015,
Lacaze et al. 2015, Figure 1). An understanding of how a representative intertidal system
responds to chronic exposure of SMX and TRI mixtures offers a more complete picture
of the environmental consequences antibiotic pharmaceuticals have when released into
marine ecosystems at ever-growing rates, and sheds light on the potential for cascading
trophic effects.
4

Figure 1.1 Conceptual model of knowns, questions, and hypotheses framing this thesis
investigating long-term effects of pharmaceutical contaminants on marine intertidal
species.
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Chapter 2: Effects of antibiotics mixtures at environmentally-relevant
concentrations on marine microalgae
Introduction
Photosynthetic algae are part of the base of the food web in aquatic ecosystems,
and population level alterations to these photoautotrophic organisms can result in
quickly-realized and severe bottom-up effects at higher trophic levels (Nie et al. 2013).
Thus, microalgae are often used as indicators of pollution and water quality (McCormick
and Cairns Jr. 1994). Pharmaceuticals, which are widely used in both human and
veterinary medicine, follow many documented pathways into the environment and may
be significant stressors to organisms (Boxall 2004).
Pharmaceutical compounds are often not fully metabolized by the human body,
remaining biologically active in waste. In turn, onsite and wastewater treatment plant
systems fail to remove all pharmaceuticals before releasing effluent water into the
environment. Moreover, improper disposal of expired or unneeded pharmaceuticals,
industrial emissions, and agricultural uses (e.g., antibiotic use in aquaculture) also
contribute to environmental pollution (Boxall 2004). As a result, a vast array of
pharmaceuticals has been detected in marine and freshwater organisms, sediments, and
waters, including drinking water, at concentrations of high ng/L with potential
unintended effects on non-target organisms and food webs (Daughton and Ternes 1999).
Aquatic studies of pharmaceutical effects on microalgae have focused on acute
toxicity of freshwater microalgae, with most experimental tests completed within 96
hours (Halling-Sørensen 2000, Cleuvers 2003, Eguchi et al. 2004, El-Bassat et al. 2012,
González-Pleiter et al. 2013). There is a lack of chronic effects studies using
6

environmentally-relevant concentrations of drugs. In several studies of pharmaceutical
drugs applied to multiple freshwater organisms (such as algae, Daphnia, fish, and
amphibians), the drugs exhibited the greatest effects on freshwater microalgae (Isidori et
al. 2005, El-Bassat et al. 2012). Isodori et al. (2005) found that out of the six antibiotics
studied, most were bioactive at concentrations in the order of µg/L, mainly for freshwater
algae, and the drugs were one or two orders of magnitude less active in rotifers and
crustaceans. Thus, microalgae may be among the most sensitive aquatic organisms to
antibiotics.
Antibiotics target bacteria rather than eukaryotic algae, but these drugs may also
cause detrimental effects to algae, as some algal organelles (such as the chloroplast and
mitochondria) retain similarities to bacteria in structure and evolutionary origin (Vannini
et al. 2011, Guo et al. 2015). Many organisms also have complex interactions with
bacteria, and the application of low-levels of antibiotics over the long term may disrupt
these interactions, leading to the suppression of population growth rates and potential
effects on the availability of algae as a food source for higher trophic levels. Guo et al.’s
(2015) review of the pharmaceutical risks to primary producers found that some
antibiotics could pose a potential threat to algal species, with blue-green and green algae
being particularly sensitive. However, they note many unstudied aspects of
pharmaceutical risks, such as pharmaceutical mixture effects on algal species to identify
interactive effects, and the need for studies of long-term effects of pharmaceuticals at
environmentally-relevant concentrations (Guo et al. 2015).
Pharmaceutical exposure studies on marine organisms are notably lacking (Gaw
et al. 2014). In the present study, I examine the growth response of three marine
7

microalgal species to treatment at environmentally-relevant levels of antibiotic mixtures
of sulfamethoxazole (SMX) and trimethoprim (TRI). Sulfamethoxazole and trimethoprim
are often prescribed together to treat a suite of bacterial infections. In a 5:1 ratio, they
comprise the antibiotic drug Bactrim, which is on the World Health Organization’s List
of Essential Medicines (WHO 2015). Their mode of action is inhibiting synthesis of the
bacterial enzyme tetrahydrofolic acid, a folic acid derivative (Boothe 2015); however,
they interrupt the synthesis chain at two different points, lending to synergistic effects in
combination due to their different target sites (Eguchi et al. 2004). Worldwide, SMX and
TRI have been commonly detected in marine and estuarine environments at
concentrations up to 870 ng/L for trimethoprim and 765 ng/L for sulfamethoxazole (Gaw
et al. 2014). Toxicity of these drugs has been identified in freshwater organisms, with
acute synergistic effects observed in mixtures of the two (Eguchi et al. 2004); however,
little research has examined possible chronic exposure (weeks to months) effects on
marine microalgae at environmentally-relevant concentrations. These low-level
concentrations and antibiotic mixtures more closely mimic real-world exposures.
Isochrysis galbana, Chaetoceros neogracile, and Nannochloropsis oculata are all
eukaryotic marine microalgal species commonly cultured for use in rearing marine
organisms such as bivalves, shrimp, and fish (Spolaore et al. 2006). Characteristics such
as nutritional requirements for the predator, sufficient cell sizes and digestibility of the
microalgae, reproduction rate, and reliable and sustainable culturing in standardized
commercial growing systems all determine their applicability in the rearing of different
marine organisms. Among the three species, N. oculata and C. neogracile are both within
Phylum Heterokontophyta, which contains more than 25,000 species (of mostly algae)
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and are thus most closely related evolutionarily. C. neogracile is a centric non-chain
forming marine diatom, 6-9µm in width and 2-3µm in length, in the class
Bacillariophyceae. N. oculata, is in the class Eustigmatophyceae and differs from other
related microalgae in that it has chlorophyll a and completely lacks chlorophyll b and c
(Simionato et al. 2013). Compared to closely related taxa, N. oculata are smaller, with a
diameter of 2 to 3 µm and have a simple structure with reduced structural elements
(Simionato et al. 2013). I. galbana is in Phylum Haptophyta, which is characterized by a
unique organelle, the haptonema. I. galbana is a single-celled marine microalgal species
ranging in length from 3-6 µm and is found in a wide geographic range, including in the
northeastern Pacific. I. galbana has commonly been used as an indicator species among
primary producers in aquatic food chains and ecosystems (Lai et al. 2009). Huang et al.
2014 found the sulfonamide drug, sulfamonomethoxine, exhibited greater toxicity to I.
galbana than to Daphnia and fish, and concluded that this drug could be a risk to aquatic
organisms in waters. These species reproduce asexually by cell division in the presence
of proper light and nutrient conditions.
This study tested the hypothesis that exposure to SMX and TRI over the course of
several weeks would significantly suppress algal growth due to the sensitivities of
microalgae to pharmaceuticals, and that these effects would be more pronounced in
mixture treatments, and at higher concentrations, due to the documented synergistic
nature of the two drugs.

9

Methods
Algal Cultures
The marine microalgal species, Isochrysis galbana and Chaetoceros neogracile
were provided by B. Schoolfield and K. Preston from the Hatfield Marine Science
Center, Newport, OR, while Nannochloropsis oculata was purchased from Mercer of
Montana, LLC. All three species were cultivated in 33 ppt seawater, prepared by adding
synthetic sea salt (Instant Ocean) to deionized water and adjusting the solution to 33 ppt;
essential Proline F/2 algal nutrients were added (with sodium metasilicate also added in
recommended quantities for the diatom C. neogracile) (Price et al. 1989, RebollosoFuentes et al. 2001). Algae were grown at 15 ± 1 °C under a 12 hr light/dark illumination
cycle with daily gentle shaking utilizing four 32-watt natural full-spectrum bulbs with
2850 lumens each.
Antibiotics
Sulfamethoxazole and trimethoprim were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Stock solutions of each antibiotic were prepared by dissolving the
selected antibiotic in deionized water, and concentrations of each antibiotic were then
adjusted from each stock solution using serial dilutions, with negligible volumes of 30-34
µl added to each experimental jar every 10 days to mimic effluent pulses. The half-life
for primary degradation of trimethoprim in waters is estimated to be >42 days, and for
sulfonamide drugs >21 days (Kümmerer 2008).
Pilot study
An exploratory pilot study was performed prior to the full experiment to test the
ability of I. galbana to grow in the proposed laboratory set-up, and to test a cell density
10

measuring technique involving microscope slide hemocytometers. I determined that the
algae did in fact grow steadily in the laboratory over a period of several weeks before
populations crashed in the pilot study, but that the lighting was not sufficiently uniform
throughout the tank. Also, the cell counts could be assessed via microscope slides, but the
time required to perform this counting method was deemed infeasible for this set-up. As a
result of this pilot study, I changed the lighting set-up to achieve uniformity throughout
the tank, and I explored the use of an automated hemocytometer to perform algal cell
counts, which vastly improved feasibility.
Experimental Design
Algae growth rates over time were measured in response to a treatment plan
comprised of control, low, and high SMX and TRI levels in a 3x3 factorial design. High
and low antibiotic concentrations were determined based on Gaw et al. (2014) averages
of worldwide occurrence data (Table 2.1). For worldwide occurrence data, the high and
low ranges of the two drugs were averaged for all reported instances in which both were
present to arrive at the test concentrations (Gaw et al. 2014) (Table 2.1). Nine replicate
jars of each of the nine treatments were included in the study. Experimental tests were
performed using 16-oz glass jars containing 350 ml of seawater, comprised of Instant
Ocean with Proline F/2™ algal nutrients at manufacturer recommended levels. The algal
inocula were taken from homogenized cultures and added to 350 ml of test solution to
obtain initial cell densities. The jars were covered with perforated translucent covers to
prevent evaporation and contamination, but gas exchange was allowed. The jars were
gently shaken once a day. Treatments were randomly distributed within a water bath
maintained at 15 ± 1 °C and under a 12 hr full spectrum light/dark illumination cycle.
11

Cell growth lasted for 12 to 15 days for I. galbana (with counts taken for 19 days), and
21 days for C. neogracile and N. oculata and was measured at 3-day intervals. The cell
density of algae was counted by an automated hemocytometer (Beckman Coulter
Counter, dual threshold) once every 3 days, for which 100 µl of the test medium was
extracted from each jar. Growth curves of cell density over time were set up to determine
species-specific rates of algal population growth over 20 days.
Table 2.1. Antibiotic mixture treatment concentrations (high and low values are based off
of worldwide occurrence data range averages). The 9 treatment levels (grey) are
comprised of control (0), low, and high levels in every combination. For each treatment,
n=9. SMX = sulfamethoxazole, TRI = trimethoprim, with bold indicating SMX levels.
SMX

TRI

0

7.5	
  ng/L	
  (Low)	
  

75	
  ng/L	
  (High)

0

0	
  -‐	
  0

Low	
  –	
  0

High	
  -‐	
  0

8.5	
  ng/L	
  (Low)

0	
  -‐	
  Low

Low	
  –	
  Low

High	
  -‐	
  Low

85	
  ng/L	
  (High)

0	
  -‐	
  High

Low	
  -‐	
  High

High	
  -‐	
  High

Statistical analysis
Algal data were analyzed with R studio software version 0.98.1062 including the
package “ez” to calculate repeated-measures analysis of variance (ANOVA) to analyze
differences in each algal species’ population growth at sampling days throughout the
testing period (R Development Core Team 2008, Lawrence 2015). Treatment categories
and sampling date were factors with tanks included as an error term to account for the
non-independence between temporal samples. The assumption of sphericity was
12

determined for each factor using the Mauchly test and adjusted using Greenhouse-Geisser
corrections. Differences in beginning concentrations were accounted for by standardizing
to Day 0 concentrations prior to analysis. Population growth rates during the growth
phase for each algal species were analyzed. Interaction plots of final algal counts were
generated to parse out interactive drug effects when significant. Normality and
homogeneity of variances were assessed through graphical inspection of the model
residuals, and data were square-root (for C. neogracile and I. galbana) or logtransformed (for N. oculata) to meet these assumptions. Post-hoc significant differences
between treatments and controls were measured with a pair-wise Tukey test. Values were
considered significantly different at p<0.05.

Results
Algal cell density grew over time in three species of marine microalgae, but was
suppressed at higher levels of SMX for all species (Figure 2.1A-C). Treatments with
higher levels of SMX resulted in lower algal cell density over time for C. neogracile and
I. galbana and all but one treatment mixture concentration resulted in lower cell densities
over time for N. oculata as compared to the control (Figure 2.1, Table 2.2).
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B
14

C

Figure 2.1. Results of the growth phase of algal cell density treatment averages for A) I.
galbana, B) C. neogracile and C) N. oculata, averaged by antibiotic mixture treatment
levels, and standardized by Day 0 concentrations. For each treatment, n=9 (except for S2T2 for I. galbana, where n = 8). Error bars indicate ± SE of the mean.
The interaction of SMX level and time had a significant suppressive effect on the growth
of all three algal species, while the interactive effect of TRI and time also had a
significant suppressive effect on N. oculata only (Table 2.2; Figure 2.2). N. oculata
responded most sensitively to the treatments with both SMX and TRI treatment levels
suppressing algal growth, although there was no significant interactive effect of the two
drugs (Table 2.2; Figure 2.1). The interactive effect of SMX and TRI over time was
significant for I. galbana, driven by the fact that the S0-T1 treatment growth averages

15

were significantly higher than the other treatments, but overall, SMX level was a stronger
significant suppressive factor, F71,284 = 5.66, p = 0.005 (Table 2.2).
Table 2.2. Repeated-measures ANOVA results of algal growth for three algal species.
Significant factors and P-values < 0.05 are shown in bold.
Algae
Factor
SS
MS
df
F
p
Species

Isochrysis
galbana

Chaetoceros
neogracile

Nannochloropsis
oculata

SMX
TRI
Sample Date

6.27E+12
6.77E+11
8.44E+14

3.13E+12
3.39E+11
4.22E+14

2
2
2

5.66
0.61
1862.14

TRI*SMX
SMX * Sample Date
TRI * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
SMX
TRI
Sample Date
TRI*SMX
SMX * Sample Date
TRI * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
SMX
TRI
Sample Date
TRI*SMX
SMX * Sample Date
TRI * Sample Date
TRI * SMX * Date
Error among groups
Error within groups

1.79E+12
2.26E+12
9.23E+11
3.47E+12
3.93E+13
3.22E+13
1.11E+14
1.43E+11
2.28E+14
2.12E+14
9.38E+11
2.66E+11
5.97E+11
5.27E+12
1.42E+13
1.79E+13
2.30E+12
2.82E+14
1.85E+12
9.50E+12
3.54E+12
2.85E+12
3.26E+13
3.88E+13

4.47E+11
5.64E+11
2.31E+11
2.17E+11
5.53E+11
1.13E+11
5.55E+13
7.15E+10
3.26E+13
5.30E+13
6.70E+10
1.90E+10
2.13E+10
7.43E+10
5.00E+10
8.93E+12
1.15E+12
4.03E+13
4.62E+11
6.79E+11
2.53E+11
1.02E+11
4.60E+11
1.37E+11

4
4
4
16
71
284
2
2
7
4
14
14
28
72
504
2
2
7
4
14
14
28
72
504

0.81
2.49
1.02
1.91

0.005
0.545
<
0.001
0.524
0.013
0.422
0.019

7.55
0.97
1154.16
0.07
2.38
0.67
0.76

0.001
0.383
<0.001
0.990
0.003
0.800
0.814

19.70
2.54
522.69
1.02
8.81
3.28
1.32

<0.001
0.086
<0.001
0.403
<0.001
<0.001
0.126
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A

B

C

Figure 2.2. The growth phase of algal cell density for A) I. galbana, B) C. neogracile and
C) N. oculata in response to the treatment plan, averaged by the SMX concentrations
(neglecting TRI concentrations) and standardized by Day 0 concentrations. For each
SMX treatment, n = 27 (except for A, S2: n = 26). Error bars indicate ± SE of the mean.
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Discussion
This study demonstrates that prolonged exposure to environmentally-relevant
concentrations of two antibiotics affects algal population growth rates over time. When
three species of marine microalgae from two Phyla were monitored over a ~three week
exposure period to better understand how each species responds to mixtures of
antibiotics, the compounds and compound combinations that affected algal population
growth differed across species. However, SMX concentration was a significant
suppressive factor for all three species (with the interaction with time being significant
for all). N. oculata was the most sensitive of the three species with TRI also suppressing
growth rates and with seven treatment mixture combinations significantly lowering
growth. This research builds on previous studies and addresses a prior data gap of
identifying chronic exposure effects of antibiotic mixtures at environmentally-relevant
levels. By simulating chronic antibiotic mixture exposure in the laboratory, I offer a
glimpse into how these emerging contaminants may impair primary producers in marine
waters exposed to these drugs, possibly imposing bottom-up effects on marine
communities.
SMX concentrations were the main driver of algal reproduction suppression for
two of the species, while N. oculata, with the most simplified cell structure (Simionato et
al. 2013), was significantly affected by both SMX and TRI. Perhaps due to chemical
characteristics of the drugs such as solubility or degradation products, or perhaps due to
different microalgal species’ cellular structure, even species with a similar evolutionary
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lineage can exhibit differential sensitivities to pharmaceutical contaminants within the
same class (Guo et al. 2015). Thus, it is important to investigate long-term full factorial
testing on mixtures of pharmaceuticals with multiple organisms.
SMX may have had a greater effect on algal growth than TRI due to the potential
increased toxicity of the photo-degradation products of SMX in seawater (Trovó et al.
2009b). In studies of the degradation processes and products of both SMX and TRI, it has
been found that both chemicals are not readily biodegradable in seawater, but they
transform primarily through photo-degradation, which is considerably slowed in saltwater
than in freshwater (with a half-life of approximately 42 days for trimethoprim and 21
days for sulfonamide drugs in seawater) (Benotti and Brownawell 2007, 2009, Kümmerer
2008, Larcher and Yargeau 2012). There has been little study of the ecological risks of
the photo-degradation products that form, but there is some indication that these products
retain the activity of the parent molecule to elicit a toxicological effect on non-target
organisms in the environment, which, in some cases, is greater than the toxicity of the
parent molecule. Trovó et al. (2009a) found that over the course of the testing period,
despite 45% mineralization in saltwater, toxicity of SMX increased from 16% to 86% in
Vibrio fischeri bacterium tests, which suggests that the intermediates generated in
saltwater are potentially more toxic. Additionally, a separate study on this subject (Trovó
et al. 2009b) found that test organisms showed an increase from 60% to 100%
immobilization over the course of the test period with SMX, with the authors concluding
that there was a higher toxicity of the photo-transformation products generated.
Trimethoprim photo-degradation studies in saltwater, though limited, indicate “only a
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small increase” in the toxicity on test organisms, with intermediates which were
moderately toxic for the organisms tested (Sirtori et al. 2010, Fatta-Kassinos et al.
2011). Toxicity as well as sub-lethal assessments of transformation products must be
included in the suite of pharmaceutical contaminant research to more closely simulate
environmental conditions.
Marine microalgae possess chloroplast and mitochondrial organelles, retaining
similarities to bacteria (the target of antibiotics) in structure and evolutionary origin, but
algae and bacteria have also co-existed for more than 200 million years, resulting in
complex interactions between them (Vannini et al. 2011, Liu et al. 2012, Guo et al.
2015). An example of this interaction is that bacteria produce and supply vitamin B12 to
some diatom species, which is essential for their successful growth (Croft et al. 2005,
Guo et al. 2015). A range of antibiotics in environmentally-relevant concentrations can
damage bacteria through dissolution of their membranes or inhibition of essential
enzymes (Schreiber and Szewzyk 2008, Duggar 2011, Ji et al. 2013). Antibiotics are
known to damage bacteria experimentally, and it is likely that similar processes are
occurring in the wild to bacteria that supply nutrients to algal species (Guo et al. 2015).
Active antibiotics may be indirectly inhibiting algal species by influencing the coexisting nutrient-supply system between marine microalgae and bacteria, which is
essential for survival (Croft et al. 2005).
Primary producers are indispensable elements of food webs and nutrient-cycling
processes in marine ecosystems; thus impacts of contaminants on microalgae might shift
the balance of the community (Kümmerer 2008, Guo et al. 2015). Our findings that
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marine microalgal species may be significantly affected by environmentally-relevant
concentrations of antibiotic mixtures serve as a foundation to understand how
pharmaceuticals are affecting marine communities through potential trophic interactions.
Pharmaceuticals should be considered significant potential stressors to vulnerable aquatic
organisms already stressed by other environmental factors such as climate change, ocean
acidification, and rising sea level (Waycott et al. 2009). There is little study of the
interactive effects of global environmental changes and pharmaceutical toxicity for
freshwater organisms and no known research for marine organisms (Kim et al. 2010).
Changes in global climate adds a layer of complication in which cell processes ranging
from photosynthesis to thermo-regulation are likely to be disrupted, leading to possible
combined algal reproductive suppression with contaminants. In a world with changing
climate, increasing coastal populations, and rising pharmaceutical use, marine organisms
are exposed to an ever-increasing array of pharmaceuticals from different classes and
with different target sites, some of which are known to negatively impact aquatic
organisms (Boxall 2004, Gaw et al. 2014, Guo et al. 2015)
Many of the effects detected would not have been identified if the study had been
run for the typical experimental periods of hours or days. For example, some algal cell
density treatment average slopes diverged halfway through the three-week study period
(and time-drug interactions were significant for all three species), indicating that longerterm effects of low concentrations of these drugs may be vastly underestimated based on
typical shorter period exposure trials. Understanding the extent to which antibiotics in
particular and pharmaceuticals in general affect marine organisms over the long-term will
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require investigation across more species, drugs, degradation products, and in
combinations. Future research in the field of pharmaceutical contaminants will require
focus on these topics to assess basic marine organismal and intra-species effects in order
to prevent cumulative potential inter-species ecosystem level effects.
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Chapter 3: Environmentally-relevant concentrations of antibiotic mixtures and
marine mussel growth, feeding, and reproduction health

Introduction
Pharmaceuticals have many pathways into the environment (through improper
disposal of drugs, veterinary use, wastewater treatment plant effluent, and aquaculture
use, for example), and have been detected in the natural environment across landscape
and waterway types, with many compounds persisting in the environment for months to
years (Daughton and Ternes 1999, Richardson et al. 2005, Boxall et al. 2012). The result
of these numerous pathways and the worldwide occurrence is that pharmaceuticals have
increasingly been recognized as emerging contaminants of concern (Monteiro and Boxall
2009, Boxall et al. 2012). Although commonly detected at relatively low concentrations
(ng/L) in the environment compared to medical dosages, pharmaceuticals are designed to
elicit biological responses on their target sites, and there exist many critical questions
regarding the effects these low concentrations have over the long term on non-target
organisms (Boxall et al. 2012). Several decades of research on xenobiotics such as PCBs
and DDT has demonstrated the hormone-mimicking, non-monotonic effects on the
reproductive systems of organisms due to exposures to those chemicals in the low ng/L
range; pharmaceuticals, as biologically-active substances developed with the intention of
disrupting specific pathways and processes in humans and organisms, must be similarly
intensively investigated for their potential long-term low-level contaminant impacts
(Colborn and Clement 1992, Halling-Sørensen et al. 1998, Boxall et al. 2012).
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Recent studies confirm that pharmaceuticals occur widely in marine and coastal
environments, but many data gaps in this field exist, including potential risk assessments
of marine organisms exposed to these drugs at environmentally-relevant levels (Cleuvers
2003, Gaw et al. 2014). Ecotoxicity studies for pharmaceuticals are commonly performed
over a relatively short time span (hours to days), utilizing high concentrations of single
drugs at a time, and assessing lethal endpoints (Láng and Kőhidai 2012, Gaw et al. 2014).
Antibiotics are among the most frequently detected prescription classes (along with betablockers and anti-inflammatory drugs) found in the environment (Láng and Kőhidai
2012). The complete environmental risk assessment of antibiotic contaminants on
organisms is deficient in several categories such as the lack of chronic, long-term data on
low concentrations, sub-lethal endpoints, and utilizing mixture concentrations. In the
wild, organisms are not being exposed to one drug at a time; they are exposed to
continuously-delivered cocktails of pharmaceuticals at low concentrations that may act
synergistically (Glassmeyer et al. 2008). Bridging the knowledge gap between
ecotoxicity studies and sub-lethal chronic ecological mixture effects requires a study
approach of a different length and scope.
Despite the focus on acute and chronic toxicity to freshwater organisms, there is a
lack of understanding of how these pharmaceuticals may impact marine organisms (Gaw
et al. 2014). In the present study, I examine whole-organism responses of marine mussels
to treatments at environmentally-relevant concentrations of antibiotic mixtures of
sulfamethoxazole (SMX) and trimethoprim (TRI). The antibiotics sulfamethoxazole
(SMX), and trimethoprim (TRI) are often prescribed together to treat a suite of bacterial
infections. In a 5:1 ratio, they comprise the antibiotic drug Bactrim, which is on the
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World Health Organization’s List of Essential Medicines (WHO 2015). Their mode of
action is inhibiting synthesis of the bacterial enzyme tetrahydrofolic acid, a folic acid
derivative (Boothe 2015); however, they interrupt the synthesis chain at two different
points, lending to synergistic effects in combination due to their different target sites
(Eguchi et al. 2004). Worldwide, SMX and TRI have been commonly detected in marine
and estuarine environments, at concentrations up to 870 ng/L for trimethoprim, and 765
ng/L for sulfamethoxazole (Gaw et al. 2014). Toxicity of these drugs has been identified
in freshwater organisms, with acute synergistic effects observed in mixtures of the two
(Eguchi et al. 2004); however, little research has examined possible chronic exposure
(weeks to months) effects on marine organisms at environmentally-relevant
concentrations. These low-level concentrations and antibiotic mixtures, more closely
mimic real-world exposures.
The California mussel, Mytilus californianus, is an important benthic foundational
species found along the west coast of North America (Suchanek 1992). These
invertebrates are efficient filter feeders, able to filter 2-3 liters of water per hour (during
which they consume marine microalgae as a food source), and they specialize in living in
large aggregations on rocky substrate in the intertidal and subtidal zones (Suchanek
1981). Fabbri and Franzellitti (2015) report that caged mollusks are increasingly used to
investigate pharmaceutical occurrence in coastal environments, since their accumulation
offers information regarding exposure levels and time. Due to the fact that bivalves are
filter-feeding and sessile organisms at the substrate-water interface, they are deemed as
effective sentinels for in-situ monitoring of micro-pollutants (Fabbri and Franzellitti
2015). For example, the blue mussel (Mytilus edulis) was found to accumulate five
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pharmaceuticals in a 6-month caging experiment off the Belgian coast (Fabbri and
Franzellitti 2015). McEneff et al. (2014) reported the occurrence of 5 pharmaceuticals
(including trimethoprim) in marine mussels during a 1-year long caging experiment along
the Irish coastline, with most of the five drugs found in mussel tissues also detected in
surface waters at average concentrations in the mid to high ng/L.
The potential toxicity and sub-lethal effects of pharmaceuticals in general and
antibiotics in particular on aquatic invertebrates is still poorly understood (Lacaze et al.
2015). For marine organisms, there are a lack of studies on whole-organism sub-lethal
effects and a lack of chronic exposure studies using environmentally-relevant
pharmaceutical concentrations. Lacaze et al. (2015) showed that antibiotics affect the
immune system of the blue mussel, Mytilus edulis, utilizing genotoxic and immunotoxic
endpoints. There is a focus in this field on sub-organismal assessment methods, where the
effects of pharmaceutical exposure on freshwater and marine bivalves are at the
molecular level, such as disturbed enzyme functions, DNA damage, and modulated gene
expression (Franzellitti et al. 2013, Gonzalez-Rey and Bebianno 2013, Lacaze et al.
2015). There are also cellular level studies, with assessments of increased oxidative
stress, cytotoxicity and immunotoxicity (Gust et al. 2012, Tsiaka et al. 2013, Lacaze et al.
2015).
Many organisms have complex interactions with bacteria (which play a role in
digestion across taxonomic groups (Eckburg et al. 2005), and it has been demonstrated
that pharmaceutical target sites in humans may have counterparts which could be present
in invertebrates, and possibly affect comparable pathways (Christen et al. 2010). Building
on this, I examined the response of marine mussels in the form of growth and mass, algal
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clearance rates, and condition and reproductive indices to environmentally-relevant
mixtures of the antibiotics sulfamethoxazole (SMX) and trimethoprim (TRI). I
hypothesize that these tissue-level and whole-organism level marine mussel metrics will
be impacted by prolonged exposure to these drugs, and that interactive effects will be
apparent in mixture concentrations. The hypothesis is that antibiotic treatments will
interfere with M. californianus algal feeding rates or digestion, and will result in overall
suppression of growth, mass, condition index, and gonado-somatic index in the higher
treatment levels. I hypothesize that the effect may be more pronounced in mixture
treatments of the drugs, due to the documented synergistic effects of SMX and TRI on
organisms in combination (Nord et al. 1974). This study targets data gaps in emerging
antibiotic pharmaceutical contaminants research: 1) mixture effects of pharmaceuticals
which are known to act synergistically, 2) the impacts to whole organism physiology and
function; 3) the effects of long-term exposure periods (on the scale of months) 4) effects
of environmentally-relevant levels.

Methods
Study Organisms and Acclimation Conditions
Approximately 750 marine mussels (Mytilus californianus) between 1.5 and 2.8
cm in length were collected on September 7, 2015 from Rockaway Beach in Tillamook
County, Oregon. Mussels were first grouped for 1 week in 23 liters of Instant Ocean
seawater in a tank with 32 parts per thousand (ppt) salinity, and water quality was
monitored to ensure appropriate ammonia, nitrite, nitrate, and pH conditions. Mussels
were randomly distributed to test jars to acclimatize for 2 weeks, with 9 mussels per 16
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oz. jar, in 400 ml of water. Throughout the experiment, mussels were kept in Instant
Ocean seawater pre-treated with ammonia, nitrite, and nitrate reducers to maintain tank
environments.
Experimental Design
Experimental tests were performed over 12 weeks using 16-oz glass jar tanks
comprised of Instant Ocean seawater maintained at 32 ppt salinity. Mussels jars were
kept in a 15 ± 1 °C water bath, using a 12 hr light/dark illumination cycle with 24
hour/day aeration. There were four 32-watt natural full-spectrum bulbs with 2850 lumens
each over the water bath. The 81 jars had full water changes every 10 days, and were
treated according to an antibiotic treatment plan, consisting of control, low and high
concentrations of SMX and TRI antibiotic concentrations determined based on Gaw et al.
(2015) averages of worldwide occurrence data, in a 3x3 factorial design (Table 3.1). With
the worldwide occurrence data, the high ranges were averaged and the low ranges were
averaged of SMX and TRI individually for all reported instances in which both were
present to arrive at the test concentrations (Table 3.1) (Gaw et al. 2014). These antibiotic
mixture treatments were applied every 10 days (mimicking effluent pulse effects)
following the full water changes, with nine replicate jars for each mixture treatment
concentration described in Table 3.1.
Each jar began with 9 mussels per jar, and 3 mussels were sub-sampled from
each jar at week 6 in order to measure tissue indices. A background mortality rate of less
than 3.6% was experienced throughout the duration of the 12-week experiment. All
Instant Ocean seawater was pre-treated with ammonia, nitrite, and nitrate reducers to
maintain tank environments, and ammonia, nitrite, nitrate, pH, and salinity levels were
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monitored in random jar checks during specified points during the water change cycle. To
ameliorate unavoidable evaporation across jars and improve water quality, every 5th day
between water changes, 50 ml of slightly under-salinated (29 ppt) saltwater was added to
all jars to bring jar levels up to 400 ml and proper salinity. Every 3 days, mussels were
fed non-viable Isochyris galbana algae based on Reed Mariculture’s™ feeding guidelines
with feeding volume scaled by the number of mussels per jar at any given time.
Table 3.1. Antibiotic mixture treatment concentrations (high and low values are based off
of worldwide occurrence data range averages). The 9 treatment levels (grey) are
comprised of control (0), low, and high levels in every combination. For each treatment,
n=9. SMX = sulfamethoxazole, TRI = trimethoprim, with bold indicating SMX levels.
SMX

TRI

0

7.5	
  ng/L	
  
(Low)

75	
  ng/L	
  (High)

0

0	
  -‐	
  0

Low	
  –	
  0

High	
  -‐	
  0

8.5	
  ng/L	
  (Low)

0	
  -‐	
  Low

Low	
  –	
  Low

High	
  -‐	
  Low

85	
  ng/L	
  (High)

0	
  -‐	
  High

Low	
  -‐	
  High

High	
  -‐	
  High

Antibiotics
Sulfamethoxazole and trimethoprim were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Stock solutions of each antibiotic were prepared by dissolving the
selected antibiotic with deionized water, and concentrations of each antibiotic in
experimental tests were then adjusted from each stock solution using serial dilutions,
allowing for a negligible volume of 30-34 µl added to each jar every 10 days, to mimic
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effluent pulses. The half-life in water for primary degradation of trimethoprim is
estimated to be >42 days, and for sulfonamide drugs is >21 days (Kümmerer 2004).
Endpoints
In response to the antibiotic treatment levels applied, various endpoints were measured in
the mussels throughout the 12-week experiment (Table 3.2)
Table 3.2. Endpoints measured in test mussels in response to treatment of antibiotics
SMX and TRI mixtures.
Endpoints Measured
(in response to treatments)

Frequency

Growth rates: dimensions (L, W, H), mass

Week 0, 6, 9, 12

Feeding rates (algal clearance)

Week 2, 4, 6, 8, 10, 12

Condition Index (CI),
Gonado-Somatic Tissue Index (GSI)

Week 6, 12

Mussel Growth
To examine differences in growth rates over time, all mussels in the experiment
were measured in three dimensions using calipers (Mitutoyo 500 196-30) accurate to
±0.01 mm, and were massed using a balance accurate to ±0.001 grams (Southern
Laboratories) (Suchanek 1981). Length here is defined as the maximum anterior (umbo)
dimension to the posterior dimension, height as maximum dorsal-ventral dimension of
the shell measured perpendicular to the hinge, and width as the maximum left-right
dimension with both valves appressed (Larson et al. 2014). These measurements were
taken at weeks 0, 6, 9, and 12 (at the end of the experiment). Percent change in
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dimensions was calculated as % change = (Dimensiont – Dimension0)/Dimension0)) *
100 for each dimension measurement for time “t” as compared to initial time “0,” and the
response variable approximation of mussel shell volume (mm3) was taken as Length *
Width * Height of each mussel at each sampling event. At week 6 sampling, within-tank
means are comprised of 9 mussels per tank, and at weeks 9 and 12, 6 mussels per tank (as
mussels were subsampled at week 6).
Feeding Rates
Following the methods of Berg et al. (1996) for measuring mussel feeding rates
(algal clearance), three randomly selected jars per treatment level were monitored
biweekly, and algal cell densities within the jars were measured with a Beckman Coulter
Counter at two time points: 1) just after feeding, and 2) approximately 2-3 hours postfeeding to determine the uptake rate by the filter-feeding mussels. Exact time is
accounted for (in # of minutes) in the equation: Clearance rate = [(lnC0 – lnCt) – (lnC’0 –
lnC’t)] * V / t, where C0 = algal concentration at the start of the test period, Ct = algal
concentration at the end of the test period, C’0 = algal concentration of the control jar at
the beginning of the experiment, C’t = algal concentration of the control jar at the end of
the test period, V = experimental volume, and t = time (minutes). Clearance rates were
divided by the number of mussels per jar at each sampling event to obtain a per mussel
average. Control jars with algae added but without mussels were measured to identify
algal settling rates on the glassware. Randomly selected jars were also measured to
confirm that pre-feeding background rates of particles within the same size class were not
significant in these particle counter measurements.
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Body condition: Gonado-somatic Index & Condition Index
Methods for measuring gonado-somatic index (GSI) and mussel condition index
(CI) are based on Schiedek et al. (2006). At week 6, three mussels from each jar were
sub-sampled and frozen to measure CI and GSI (for reproductively mature mussels), and
again at week 12. The measurements were: CI = tissue dry weight (g)/shell length (cm) ·
100], and GSI = gonad weight (g)/somatic weight (g) · 100 (standardized to shell length
at each sampling period). Mussels were dissected and frozen, and then dried for 48 hours
at 60ºC to obtain dry tissue weights (Schiedek et al. 2006).
Data Analysis
For each analysis, within-tank means for all mussel growth parameters, GSI, CI,
and algal clearance rates were calculated. Repeated-measures two-way ANOVAs were
calculated using the R studio version 0.98.1062 package “ez” to analyze differences in
parameters at different treatment levels and sub-sample time periods (R Development
Core Team 2008, Lawrence 2015). Antibiotic treatment levels of both SMX and TRI and
sampling date were factors, with tank number included as an error term to account for the
non-independence between temporal samples. The assumption of sphericity was tested
for each parameter using the Mauchly test and adjusted using Greenhouse-Geisser
corrections. Normality and homogeneity of variance were assessed through graphical
inspection of the model residuals, and data were either square-root or log-transformed to
meet assumptions. Post-hoc multiple pair-wise comparisons between treatment groups
and sample dates were performed and a Bonferroni correction was applied. For
parameters in which an interactive effect was significant, an interaction plot was
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generated and examined for the parameter’s final sampling date. Effects were considered
significant at or below α=0.05.
Results
Mussel growth
Total percent change in mussel volume was significantly affected by contaminant
concentration, particularly by SMX level (Table 3.3, Figure 3.1A and B, Figure 3.2A),
with faster overall growth in control groups (Figure 3.1A, Figure 3.2A). While there was
also an effect of the sample date on percent change in mussel volume, treatment effects
were not dependent on sample date, and there was no effect of TRI or interactive drug
effect (Table 3.3).
Overall growth in percent change of shell length followed a different pattern over
time with mussels exposed to contaminants having the greatest increase in length.
Change in shell length was significantly increased by sample date and TRI * SMX *
Date, with the interaction of the two drugs increasing percent change in length over time
(Figure 3.1C and D, Figure 3.2B, Table 3.3). The extent of this percent change in length
after 12 weeks [0.45 (SE ±0.04) %], however, was less overall than the percent change in
width [1.39 (SE ±0.06) %] for all treatments (Figure 3.1E and F, Figure 3.2C). Percent
change in mussel width was significantly suppressed by higher SMX levels, but was not
significantly affected by levels of TRI concentrations (Table 3.3, Figure 3.1E and F).
Width percent change was significantly less in the highest (S2) treatment mussels as
compared to controls by the end of the study (p=0.005). Percent change in mussel height
was largely negative over time, but was significantly suppressed by higher SMX levels
(Table 3.3, Figure 3.1G and H, Figure 3.2D), with lower overall percent change in height
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in S2 than in control groups (Figure 31.G). Interactively, TRI and SMX significantly
increased height in the S1-T2 treatment by week 12, but overall SMX elicited the most
significant suppressive effect (F72, 144 = 8.48, p=<0.001).
Mussel wet biomass percent change was significantly affected by the interactions
of SMX * Date (Table 3.3). Week 6 control SMX mussels (S0) had a significantly lower
percent change in wet biomass than the highest treatment (S2, p=0.049), but by Week 12,
these same controls had a higher average percent change in mass than the other
treatments, though not significantly different (Table 3.3, Figure 3.1I, Figure 3.2E). TRI *
SMX interactions resulted in increased mass in S2-T2 treated mussels by week 12 (Table
3.3, Figure 3.1I, Figure 3.2E). Condition indices elucidate this further by standardizing
these mass changes by dry tissue weight and shell length (Figure 3.3A and B).
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G
D

H
D

I
E

J
E

Figure 3.1. The average percent change in mussel growth parameters of total shell
volume (A and B), length (C and D), width (E and F), height (G and H), and mass (I and
J) across SMX and TRI treatment groups over the experimental period. Error bars reflect
± SE of the mean.
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D

E

Figure 3.2. The average percent change in mussel growth parameters of total shell
volume (A), length (B), width (C), height (D), and mass (E) across all SMX and TRI
treatment mixtures over the experimental period. Error bars reflect ± SE of the mean.
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Table 3.3. Repeated-measures ANOVA results for growth factors. Response variables
were log-transformed (volume) or square-root transformed (L, H, W, Mass). SMX or TRI
refers to antibiotic concentration levels; significant factors (p< 0.05) are shown in bold.
Growth
parameter
Factor
SS
MS
df
F
p
(% change)

Volume

Length

Height

Width

Mass

TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups

18.60
77.59
24.52
8.90
3.19
3.79
9.25
421.70
91.62
5.57
3.75
17.59
2.65
0.87
0.27
4.31
49.73
9.39
4.73
55.61
1.74
30.46
4.73
3.07
3.95
236.16
24.22
0.75
12.71
4.41
6.26
0.38
0.87
1.41
83.54
25.34
6.32
2.40
281.06
107.59
3.15
12.61
11.56
416.47
145.92
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9.30
38.80
12.26
2.22
0.80
0.95
1.16
5.86
0.64
2.79
1.88
8.80
0.66
0.22
0.07
0.54
0.69
0.07
2.36
27.81
0.87
7.62
1.18
0.77
0.49
3.28
0.17
0.38
6.35
2.21
1.57
0.10
0.22
0.18
1.16
0.18
3.16
1.20
140.53
26.90
0.79
3.15
1.44
5.78
1.01

2
2
2
4
4
4
8
72
144
2
2
2
4
4
4
8
72
144
2
2
2
4
4
4
8
72
144
2
2
2
4
4
4
8
72
144
2
2
2
4
4
4
8
72
144

1.59
6.62
19.27
0.38
1.25
1.49
1.82

0.211
0.002
<0.001
0.822
0.292
0.209
0.078

4.03
2.71
134.84
0.96
3.34
1.03
8.25

0.021
0.07
<0.001
0.44
0.012
0.39
<0.001

0.72
8.48
5.16
2.32
7.04
4.57
2.94

0.490
<0.001
0.007
0.065
<0.001
0.002
0.005

0.32
5.48
12.53
1.35
0.54
1.24
1.00

0.724
0.006
<0.001
0.260
0.706
0.296
0.435

0.55
0.21
138.68
4.65
0.78
3.11
1.43

0.581
0.813
<0.001
0.002
0.543
0.017
0.191

Feeding Rates
At most sample periods, feeding rates were not significantly affected by experimental
parameters, except for sample date (Table 3.4). Algal clearance rates by control mussels
were significantly higher than treatment mussels of aggregated SMX levels only on
experimental Day 30 [S0: 0.25 (SE 0.03) cells mL-1 min-1 versus S1: 0.17 (SE 0.03) cells
mL-1 min-1 and S2: 0.16 (SE 0.02) cells mL-1 min-1, F2,24 = 5.14, P = 0.013 ].

Body condition: Gonado-somatic Index & Condition Index
The mean tank condition index (CI) was affected by both SMX and TRI treatment
levels over time. Mean CI significantly decreased from week 6 to week 12 in the highest
treatment concentrations of SMX and TRI, while it increased for control groups and
lower treatment concentrations (Figure 3.3A and E). The following factors significantly
influenced CI: TRI levels, SMX levels, interactions of TRI * Sample Date, SMX *
Sample Date, and TRI * SMX * Date (Table 3.4, Figure 3.4A and E). The interaction of
SMX and TRI treatments suppressed CI in mixture treatment levels as compared to the
treatment concentrations without TRI.
The gonado-somatic index (GSI) of mussels (standardized to mussel length) was
significantly influenced by TRI and the interaction of TRI * SMX (Figure 3.3C and D,
Table 3.4). Interactively, the highest levels of TRI and SMX resulted in higher GSI at
week 12. The week 6 GSI:length index was significantly higher in control treatment and
treatments with SMX only than those treated with any concentration of TRI (Figure
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3.3B). Week 12 GSI:length exhibited higher mean GSI:length values for control S0
mussels than S2 treated mussels, though not significantly (Figure 3.3C).
c

b
a

a
b
a

A

B
a
b

b
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D
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Figure 3.3. Mean mussel tissue indices at weeks 6 and 12 in response to antibiotic
treatments for A) CI by SMX level, B) CI by TRI level, C) GSI by SMX level, D) GSI by
TRI level, D) CI by SMX and TRI mixtures and E) GSI by SMX and TRI mixtures.
Lowercase letters and asterisks (*=different than control) represent significant
differences, p<0.05.
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Table 3.4. Repeated measures ANOVA results for mean tank body condition indices (CI
and GSI) and algal clearance rates, including 2nd, and 3rd order interactions. Response
variables were log-transformed. SMX or TRI refers to antibiotic concentrations;
Significant factors and p-values < 0.05 are shown in bold.
Dependent
variable

Condition
Index
(CI)

Gondo-somatic
index
(GSI)

Clearance rate

Factor

SS

MS

df

F

p

TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups
TRI
SMX
Sample Date
TRI*SMX
TRI * Sample Date
SMX * Sample Date
TRI * SMX * Date
Error among groups
Error within groups

3.04E-05
6.65E-05
1.38E-06
1.02E-05
2.90E-05
4.84E-05
2.65E-05
9.23E-05
1.02E-04
3.68E-04
5.27E-05
1.89E-05
6.17E-05
3.73E-05
8.61E-07
2.97E-05
2.83E-04
3.78E-04
0.05
0.03
1.13
0.24
0.12
0.21
0.35
11.97
1.73

1.52E-05
3.33E-05
1.38E-06
2.55E-06
1.45E-05
2.42E-05
6.63E-06
1.71E-06
1.89E-06
1.84E-04
2.63E-05
1.89E-05
1.54E-05
1.87E-05
4.31E-07
7.43E-06
5.24E-06
7.00E-06
0.02
0.02
0.23
0.06
0.01
0.02
0.02
0.67
0.02

2
2
1
4
2
2
4
54
54
2
2
1
4
2
2
4
54
54
2
2
5
4
10
10
20
18
90

8.90
19.46
0.73
1.49
7.69
12.82
3.51

<0.001
<0.001
0.396
0.218
0.001
<0.001
0.013

5.02
1.80
0.17
2.94
2.67
0.06
1.06

0.010
0.175
0.679
0.028
0.079
0.940
0.384

0.24
0.18
9.35
0.62
0.50
0.88
0.73

0.793
0.837
<0.001
0.656
0.887
0.557
0.784

Discussion
Long-term (3 month) exposure to antibiotic mixtures at environmentally-relevant
concentrations affected mussel growth rates and body condition. Although results
indicate that mussel algal clearance rates were not affected by low concentrations of
antibiotics, the growth metrics indicate a reduced ability of the mussels to assimilate their
algal feed. Specifically, whole-body metrics of fitness such as total shell volume and
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biomass growth rates, as well as body condition indices, were significantly affected over
the course of several months. Total percent change in shell volume, an aggregate measure
of each mussel’s length, width, and height, was significantly suppressed by the highest
SMX treatments. Previous research has found that mussels tend to become narrower
(longer and less wide) under conditions of high density and at low food availability, but
food and density levels were consistent across treatments in this experiment (AlunnoBruscia et al. 2001). Thus, the suppression in shell volume growth rate observed, and the
strongly suppressed width over time (which significantly diverged from controls in the
highest aggregated SMX treatment but was unaffected by TRI parameters), indicates that
antibiotic treatments may have imposed disruptions in food assimilation, possibility due
to disturbance of the mussel gut digestion microbiome (mimicking lack of food).
Possible disruptions in the gut digestion microbiome are corroborated by the fact
that mean condition index decreased in the high SMX treatment levels in the latter half of
the study. Though SMX levels are the primary driver of effects in this mixture study,
there were interactive effects between SMX and TRI for a number of parameters - both
body condition and growth dimensions. Condition index was sensitive to both SMX and
TRI, with suppressive interactive effects found with both drugs and across sample dates.
GSI on the other hand, was affected by TRI levels and positively influenced by the
interaction of TRI * SMX. Moreover, though change in shell volume was driven by SMX
level, the individual morphological components (length, width, and height) exhibited
differential sensitivities to these mixture concentrations. This indicates that mixture
studies that include measurements across diverse growth dimensions are vitally
important, as such studies more closely mimic real-world exposures and the array of
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potential effects exhibited due to the variability caused by drugs of the same class with
different target sites.
SMX may have had a greater influence on mussel growth than TRI due to the
potential increased toxicity of the photo-degradation products of SMX in seawater (Trovó
et al. 2009b). Both SMX and TRI are not readily biodegradable in seawater, but they
transform through photo-degradation with a half-life of approximately 42 days for
trimethoprim and 21 days for sulfonamide drugs (Benotti and Brownawell 2007, 2009,
Kümmerer 2008, Larcher and Yargeau 2012). Previous research shows that photodegradation products may have a greater toxicity than the parent molecule. Two studies
by Trovó et al. (2009a and 2009b) found that the toxicity of SMX increased over the
course of the test periods, with the authors concluding that the toxicity of the SMX phototransformation products generated were higher than that of the original compound.
Trimethoprim photo-degradation studies in saltwater indicate “only a small increase” in
the toxicity on test organisms, with intermediates which were moderately toxic for the
organisms tested (Sirtori et al. 2010, Fatta-Kassinos et al. 2011). Thus SMX is degrading
more quickly (with its shorter half-life), and potentially with more toxic degradation
products. Assessments of sub-lethal effects of transformation products must be included
in the suite of pharmaceutical contaminant research to more closely simulate
environmental conditions.
As efficient filter feeders, mussels in both laboratory and field studies have
demonstrated bioaccumulation of pharmaceuticals (Benotti and Brownawell 2007,
McEneff et al. 2014). Antibiotics such as SMX and TRI find their way into the
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environment mainly through effluent of wastewater treatment plants, and are considered
“pseudo-persistent” due to their continued release into the environment (González-Pleiter
et al. 2013). In laboratory settings, mussel sub-cellular endpoints such as genotoxic and
immunotoxic metrics have responded to a suite of pharmaceuticals, including antibiotics
(Gagné et al. 2006, Lacaze et al. 2015). Our findings support the indication of suppressed
health characteristics of mussels facing exposure to antibiotics. This study offers an
understanding of how a benthic foundational intertidal species responds to the presence
of SMX and TRI in the water (and likely bioaccumulation in the tissue) over the longterm using whole-organism growth rates and body condition indices, and offers insight
on environmental effects of pharmaceutical contaminants, and specifically the suite of
antibiotics, that are released into marine ecosystems.
M. californianus, is recognized as a foundation species on the Pacific coast
because it creates extensive beds that provide habitat, food and refuge for a wide range of
coastal organisms that live on exposed rocky shores (Suchanek 1992, Gaylord et al.
2011). As foundational species in rocky intertidal and subtidal ecosystems, changes in
mussel growth, condition, and reproduction could have profound effects on marine
coastal communities. This mussel plays an important role as a dominant competitor over
much of its range, as it excludes other competitors from accessing primary substrate
(Paine 1966, Gaylord et al. 2011). As such, Gaylord et al. 2011 note that “biological
diversity of many intertidal communities is linked tightly to the ecological performance
of this bivalve.” Therefore, if these important filter feeders are being exposed to
pharmaceuticals (from wastewater effluent or through other pathways), and the drugs are
45

affecting their growth and condition parameters, shifts in overall population abundance
may occur, which could have wide-ranging community-level effects.
Global human population is rapidly growing, people are increasingly using
pharmaceutical drugs, and coastal areas are home to 41% percent of the world population
(Gaw et al. 2014, Gu et al. 2010). Along with over-exploitation, habitat loss, and invasive
species, contaminants are one of the many identified anthropogenic stressors to the
coastal marine environment (Fabbri and Franzellitti 2015). Thus, important coastal
marine foundation species such as M. californianus mussels may become increasingly
vulnerable to pharmaceutical contaminants as these trends continue. Yet, there is still
much to be explored in long-term studies examining effects of the cocktail of
pharmaceuticals released into ocean waters to understand interactive and cumulative
organismal and potential ecosystem-level effects (Boxall 2004). This research
contributes to the understanding of the effects on marine mussel growth and condition in
response to long-term drug exposure to inform these potential ecosystem-level effects.
The ever-growing level of prescription drug consumption and the diverse array of drug
classes present in these habitats necessitates mixture studies to inform source
management and forestall a long-term largely irreversible contamination load in our
marine ecosystems.
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Chapter 4: Conclusions
Assessing how species across interacting trophic levels of an intertidal system
respond to the presence of sulfamethoxazole and trimethoprim in the water offers
important information on the environmental effects of anthropogenic pharmaceutical
contaminants, and specifically the suite of antibiotics, that are released into marine
ecosystems. Photosynthetic primary producer populations (marine microalgae) are
suppressed in the presence of environmentally-relevant concentrations of these drugs,
thus there is potential for cascading effects in food webs. Additionally, body condition
index, growth rate, and reproductive indicators are significantly affected by these
substances in benthic foundation species (e.g., marine mussels). The implications of this
research contribute directly to the data gaps surrounding pharmaceutical contaminants in
that it addresses long-term effects of these emerging contaminants at low-level, mixture
exposures by marine organisms.1
At this stage, there is a need for further study on the effects of many classes of
pharmaceuticals on a wide array of marine organisms (Gaw et al. 2014), but next steps
could include systematic approaches to assess higher ecosystem-level effects. Short-term
acute ecotoxicology studies likely will not reveal the non-monotonic effects that are
observed over the long-term at low concentrations of drugs. I recommend a study
approach involving first the identification of the most prevalent pharmaceutical drugs in
different classes found within coastal and estuarine environments utilizing occurrence
data, and then in a laboratory setting, systematic assessments of the long-term effects of
these most prevalent drugs on growth and reproduction of a suite of potentially sensitive
1

To access any original raw data from this study, please email JaclynRTeixeira@gmail.com
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target organisms, individually and in combination. Previous research shows that
unicellular and structurally simplistic organisms are especially sensitive to
pharmaceutical contaminants, so I would recommend that, in the marine environment,
there should be a focus on planktonic primary producers, or larval life stages of
invertebrates, as non-target organisms potentially sensitive to these drugs (Isidori et al.
2005, El-Bassat et al. 2012). Additionally, the potential for increased toxicity of photodegradation products of prevalent pharmaceuticals should be investigated rigorously in a
chemistry and ecotoxicological setting, which will inform ecological studies of the effects
of these on marine organisms resulting from long-term exposures.
The potential for antimicrobial-resistant microorganisms (and resultant effects on
organism health) due to environmental exposure to antibiotic contaminants is another
critical concern (Boxall et al. 2012). The World Health Organization (WHO) has
identified the emergence of antimicrobial resistance as one of the serious concerns for
health policies in the future (WHO (World Health Organization) 1998). Byrne-Bailey et
al. (2009) found the establishment of resistant genes in bacterial isolates from
sulfonamide antibiotic-contaminated manured agricultural soils and pig slurry, while
Gaze et al. (2011) measured differences in bacterial gene prevalence in sewage-exposed
sludge and concluded that “current waste disposal practices may present a significant risk
to human health by recycling antibiotic resistant genes of human and animal origin to the
wider environment” (Byrne-Bailey et al. 2009, Gaze et al. 2011). In Mytilus edulis
mussels, antibacterial agents used in aquaculture caused a proliferation of resistant
bacteria in mussels at higher levels in samples taken at the farm after medication than
before or in control areas (Ervik et al. 1994). However, it is noted that many questions
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remain in identifying the role pharmaceutical antibiotic contaminants play in antibiotic
resistance, as information is limited to a narrow window of antibiotic classes in certain
environments (Boxall et al. 2012). Antibiotics in the environment may result in resistant
strains of bacteria, and if humans are exposed to these resistant bacteria, there may be
impacts to human health.
This study takes a step towards informing management and policy of the
potentially harmful, anthropogenically-sourced pharmaceuticals, and their handling
techniques. Preventing further contamination is an important step in managing emerging
pharmaceutical contaminant effects. This can be achieved, in part, by informing the
public that disposing of unwanted drugs in the toilet or in landfills is harmful to the
environment, and that pharmaceuticals should instead be taken to approved drop-off
points (i.e., police stations in Oregon) for proper handling. At the time of writing, the
Food and Drug Administration’s (FDA’s) website recommends on their page titled “How
to Dispose of Unused Medicines” to first try to locate proper drop-off locations, but if
that is not possible, to throw the drugs away in plastic bags in the trash, or, if the drugs
are especially powerful or dangerous, to get rid of them immediately through flushing
down the toilet (U.S. Food and Drug Administration 2016, U.S. Food and Drug
Administration (FDA) 2016). FDA environmental assessment expert, Dr. Raanan Bloom
is quoted: “While FDA and the Environmental Protection Agency take the concerns of
flushing certain medicines in the environment seriously, there has been no indication of
environmental effects due to flushing” (U.S. Food and Drug Administration 2016).
Concurrently, the Oregon Department of Environmental Quality’s (Oregon DEQ) website
states a very different message: “Unused drugs kept in medicine cabinets, tossed in the
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garbage, or flushed down the toilet or drain can be serious threats to human and
environmental health”(Oregon Department of Environmental Quality 2016). I
recommend that these mixed messages to the public should be resolved: the FDA should
review the latest science and update their recommendations, and an easily accessible
database should be created linking to lists of designated collection sites for each state and
Drug Take-Back events (periodically sponsored by the US Drug Enforcement Agency).
Stakeholders including wastewater management boards and prescription drug disposal
sources such as hospitals should be involved in order to spark conversation in identifying
improved handling techniques of the drugs.
Coastal areas contain over 41% percent of the world population (approximately
2.3 billion people), and more than 50% of coastal countries have 80–100% of their total
population within 100 km of the coastline (Gaw et al. 2014). In addition, the use of
prescription drugs among people is rapidly increasing (Gu et al. 2010). Thus, coastal
marine and estuarine ecosystems may become especially vulnerable areas to
pharmaceutical contaminants as these trends continue. The ever-growing level of
prescription drug consumption necessitates studies to examine the environmental effects
of various classes of drugs present in these habitats to form the scientific basis on which
the reevaluation of source management may occur, in order to forestall a long-term
largely irreversible contaminant load in our marine ecosystems.
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